Idarac — Competitive Intelligence Brief

Idarac (FLOCTAFENINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: floctafenine. Area: Pain.

phase 2 floctafenine Prostaglandin G/H synthase 1 Pain Small molecule

Target snapshot

Idarac (FLOCTAFENINE). Idarac works by blocking the production of prostaglandins, which are chemical messengers that transmit pain signals to the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Idarac TARGET	FLOCTAFENINE		phase 2	floctafenine	Prostaglandin G/H synthase 1
Joicela	LUMIRACOXIB	Novartis Pharmaceuticals UK Limited	marketed	lumiracoxib	Prostaglandin G/H synthase 1	2005-01-01
Etocox	ETORICOXIB		marketed	etoricoxib	Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1	2002-01-01
Colazal	BALSALAZIDE	Valeant Pharms Intl	marketed	Aminosalicylate	Prostaglandin G/H synthase 1	2000-01-01
MOFEZOLAC	MOFEZOLAC		marketed	mofezolac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1	1994-01-01
DEXIBUPROFEN	DEXIBUPROFEN		marketed	dexibuprofen	Prostaglandin G/H synthase 1	1994-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (floctafenine class)

1. · 1 drug in this class